email article An immunotherapy combination for metastatic castration-resistant prostate cancer (mCRPC) failed to hit a response target but still exceeded historical results, a small prospective study showed. Ten of 35 (28.6%) patients responded to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy). The activity fell short of the 40% threshold for a positive outcome but well above the historical response rate for immunotherapy in patients previously treated with docetaxel. The safety profile of the combination was consistent with prior clinical experience, reported Mark Linch, MD, PhD, of University College London, at the American Association for Cancer Research virtual meeting. "Responders were enriched with patients with mismatch repair or BRCA 1 and 2," said Linch. "We believe that further study of nivolumab and ipilimumab i biomarker-selected patients with metastatic castration-resistant prostate cancer is warranted. The rate of incomplete treatment was high, suggesting that alternate dosing schedules may be required."